EVEREST II high risk study based UK cost-effectiveness analysis of MitraClip® in patients with severe mitral regurgitation ineligible for conventional repair/replacement surgery

References

• Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;52:676-85
   PubMed Web of Science ®Google Scholar
• Grigioni F, Tribouilloy C, Avierinos JF, et al; MIDA Investigators. Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. JACC Cardiovasc Imaging 2008;1:133-41
   PubMed Web of Science ®Google Scholar
• Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005;352:875-83
   PubMed Web of Science ®Google Scholar
• Goldsmith IR, Lip GY, Patel RL. A prospective study of changes in the quality of life of patients following mitral valve repair and replacement. Eur J Cardiothorac Surg 2001;20:949-55
   PubMed Web of Science ®Google Scholar
• Rimington H, Weinman J, Chambers JB. Predicting outcome after valve replacement. Heart 2010;96:118-23
   PubMed Web of Science ®Google Scholar
• Steptoe A, Mohabir A, Mahon NG, et al. Health related quality of life and psychological wellbeing in patients with dilated cardiomyopathy. Heart 2000;83:645-50
   PubMed Web of Science ®Google Scholar
• Supino PG, Borer JS, Franciosa JA, et al. Acceptability and psychometric properties of the Minnesota Living with Heart Failure Questionnaire among patients undergoing heart valve surgery: validation and comparison with SF-36. J Card Fail 2009;15:267-77
   PubMed Web of Science ®Google Scholar
• Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace 2011;13(2 Suppl):ii13-ii17
   PubMedGoogle Scholar
• Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-68
   PubMed Web of Science ®Google Scholar
• Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006;48:1-148
   PubMedGoogle Scholar
• Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J 2007;28:1358-65
   PubMed Web of Science ®Google Scholar
• Alegria-Barrero E, Chan PH, Paulo M, et al. Edge-to-edge percutaneous repair of severe mitral regurgitation. Circ J 2012;76:801-8
   PubMed Web of Science ®Google Scholar
• Ussia GP, Cammalleri V, Scandura S, et al. Update on percutaneous mitral valve therapy: clinical results and real life experience. Minerva Cardioangiol 2012;60:57-70
   PubMed Web of Science ®Google Scholar
• Ussia GP, Cammalleri V, Sarkar K, et al. Quality of life following percutaneous mitral valve repair with the MitraClip System. Int J Cardiol 2012;155:194-200
   PubMed Web of Science ®Google Scholar
• Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair the EVEREST-II (Endovascular Valve Edge-to-Edge Repair) high risk study. J Am Coll Cardiol 2012;59:130-9
   PubMed Web of Science ®Google Scholar
• Rudolph V, Knap M, Franzen O, et al. Echocardiographic and clinical outcomes of MitraClip therapy in patients not amenable to surgery. J Am Coll Cardiol 2011;58:2190-5
   PubMed Web of Science ®Google Scholar
• Auricchio A, Schillinger W, Meyer S, et al; PERMIT-CARE Investigators. Correction of mitral regurgitation in nonresponders to cardiac resynchronization therapy by MitraClip improves symptoms and promotes reverse remodeling. J Am Coll Cardiol 2011;58:2183-9
   PubMed Web of Science ®Google Scholar
• Maisano F, La Canna G, Colombo A, et al. The evolution from surgery to percutaneous mitral valve interventions: the role of the edge-to-edge technique. J Am Coll Cardiol 2011;58:2174-82
   PubMed Web of Science ®Google Scholar
• Schillinger W, Athanasiou T, Weicken N, et al. Impact of the learning curve on outcomes after percutaneous mitral valve repair with MitraClip and lessons learned after the first 75 consecutive patients. Eur J Heart Fail 2011;13:1331-9
   PubMed Web of Science ®Google Scholar
• Maisano F, Godino C, Giacomini A, et al. Patient selection for MitraClip therapy impaired left ventricular systolic function. Minerva Cardioangiol 2011;59:455-71
   PubMed Web of Science ®Google Scholar
• Maisano F, Godino C, Giacomini A, et al. Clinical trial experience with the MitraClip catheter based mitral valve repair system. Int J Cardiovasc Imaging 2011;27:1155-64
   PubMed Web of Science ®Google Scholar
• Maisano F, Taramasso M, Cioni M, et al. Review of the MitraClip clinical evidence. Minerva Cardioangiol 2012;60:85-93
   PubMed Web of Science ®Google Scholar
• Rogers JH, Franzen O. Percutaneous edge-to-edge MitraClip therapy in the management of mitral regurgitation. Eur Heart J 2011;32:2350-7
   PubMed Web of Science ®Google Scholar
• Franzen O, van der Heyden J, Baldus S. MitraClip® therapy in patients with end-stage systolic heart failure. Eur J Heart Fail 2011;13:569-76
   PubMed Web of Science ®Google Scholar
• Tamburino C, Immè S, Barbanti M, et al. Reduction of mitral valve regurgitation with Mitraclip® percutaneous system. Minerva Cardioangiol 2010;58:589-98
   PubMed Web of Science ®Google Scholar
• Tamburino C, Ussia GP, Maisano F, et al. Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting. Eur Heart J 2010;31:1382-9
   PubMed Web of Science ®Google Scholar
• Feldman T, Kar S, Rinaldi M, et al; EVEREST Investigators. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 2009;54:686-94
   PubMed Web of Science ®Google Scholar
• Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1395-406
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Schulpher M. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press, 2006
   Google Scholar
• Abbott Vascular. A study of the evalve cardiovascular valve repair (MitraClip) System Endovascular Valve Edge-Edge REpair STudy (EVEREST-II): EVEREST -II High Risk Registry Clinical Report. (Data on file)
   Google Scholar
• Feldman T, Foster E, Kar S, et al; on behalf of the EVEREST II Investigators. Randomized comparison of percutaneous mitral valve repair and surgery for mitral regurgitation. 2 year results of the EVEREST II randomized controlled trial. Presented at ACC 2011. San Francisco, California, USA. June 29--July 1, 2011. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_425339.pdf. Accessed February 2012
   Google Scholar
• Aronson D, Goldsher N, Zukerman R et al. Ischemic mitral regurgitation and risk of heart failure after myocardial infarction. Arch Intern Med 2006;166:2362-8
   PubMed Web of Science ®Google Scholar
• British National Formulary. UK department of health. www.bnf.org
   Google Scholar
• National Health Service Schedule of Reference costs 2008/2009. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591
   Google Scholar
• Eurostat - Histological EU inflation rates (HICP - all items). 2011. Available by the European Commission
   Google Scholar
• Kind P, Hardman G, Macran S. UK Population Norm for EQ-5D - CHE discussion paper. 1999. http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20172.pdf. Available from the University of York, UK website
   Google Scholar
• Kirsch J, McGuire A. Establishing health state valuations for disease specific states: an example from heart disease. Health Econ 2000;9:149-58
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Campbell HE, Plumb JM. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur J Health Econ 2006;7:72-8
   PubMedGoogle Scholar
• Saborido CM. Systematic review and cost effectiveness evaluation of ‘pill-in-the-pocket’ strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy. Health Technol Assess 2010;14:iii-iv, 1-75
   Google Scholar
• Watt M, Mealing S, Eaton J, et al. Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart 2012;98:370-6
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Methodological guideline for assessing cost-effectiveness. London, UK: NICE. http://www.nice.org.uk/media/68D/29/The_guidelines_manual_2009_-_Chapter_7_Assessing_cost_effectiveness.pdf
   Google Scholar
• Linde C, Mealing S, Hawkins N, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). Eur Heart J 2011;32:1631-9
   PubMed Web of Science ®Google Scholar
• Gada H, Kapadia SR, Tuzcu EM, et al. Markov model for selection of aortic valve replacement versus transcatheter aortic valve implantation (without replacement) in high-risk patients. Am J Cardiol 2012;109:1326-33
   PubMed Web of Science ®Google Scholar
• Briggs A, Mihaylova B, Sculpher M, et al. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart 2007;93:1081-6
   PubMed Web of Science ®Google Scholar
• Henriksson M, Epstein DM, Palmer SJ, et al. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart 2008;94:717-23
   PubMed Web of Science ®Google Scholar
• Sculpher MJ, Lozano-Ortega G, Sambrook J, et al. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am Heart J 2009;157:845-52
   PubMed Web of Science ®Google Scholar
• Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J 2005;26:2681-8
   PubMed Web of Science ®Google Scholar
• Griffin SC, Barber JA, Manca A, et al. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ 2007;334:624
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. 20th March, 2013. US Food and Drug Agency. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM345235.pdf. Accessed 13 April, 2013
   Google Scholar
• Medical Services Advisory Committee. 2013. Australian Medical Services Advisory committee. http://www.msac.gov.au/internet/msac/publishing.nsf/Content/01C3008A7A465AEACA25794F001FB36E/$File/MSAC-App-1192-Minutes-Nov2012-redacted.pdf. Accessed 13th April, 2013
   Google Scholar
• NHS Commissioning Board. Clinical Commissioning Policy Statement: MitraClip. www.engage.commissioningboard.nhs.uk. Accessed 13th April, 2013
   Google Scholar
• Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11
   PubMed Web of Science ®Google Scholar
• Garcia Meta. Evaluación económica del tratamiento de la del tratamiento de la insuficiencia de la válvula mitral. Sevilla, Spain: Spanish Ministerio De Santidad Y Consumo, 2008. http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_2006-31_Insuf_valv_mitral.pdf
   Google Scholar
• Baldus S, Schillinger W, Franzen O, et al. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 2012;14:1050-5
   PubMed Web of Science ®Google Scholar
• Conradi L, Treede H, Franzen O, et al. Impact of MitraClip™ therapy on secondary mitral valve surgery in patients at high surgical risk. Eur J Cardiothorac Surg 2011;40:1521-6
   PubMed Web of Science ®Google Scholar
• Rudolph V, Knap M, Franzen O, et al. Echocardiographic and clinical outcomes of MitraClip therapy in patients not amenable to surgery. J Am Coll Cardiol 2011;58:2190-5
   PubMed Web of Science ®Google Scholar
• Treede H, Schirmer J, Rudolph V, et al. A heart team’s perspective on interventional mitral valve repair: percutaneous clip implantation as an important adjunct to a surgical mitral valve program for treatment of high-risk patients. J Thorac Cardiovasc Surg 2012;143:78-84
   PubMed Web of Science ®Google Scholar
• Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006;27:1928-32
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008;11:1131-43
   PubMed Web of Science ®Google Scholar